Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Registration Number
- NCT00124280
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study will evaluate the efficacy and safety of everolimus treatment of patients with advanced NSCLC. The rationale for investigating everolimus in advanced NSCLC previously treated with chemotherapy or chemotherapy plus EGFR inhibitors, like gefitinib or erlotinib, is based on following:
* The medical need for the better therapy for advanced NSCLC and limited efficacy of the currently available therapy in advanced NSCLC.
* Postulated association of relevant cell-signaling pathways targeted by everolimus with different aspects of oncogenesis, disease progression, and response/resistance to treatment.
* Effectiveness of everolimus and rapamycin in preclinical models of lung cancer
* Early reports of clinical responses to monotherapy with mTOR inhibitors in advanced NSCLC.
There is evidence that an enhanced PI3K/Akt/mTOR pathway, which is inhibited by everolimus, may be one of the key changes accounting for different aspects of oncogenesis, disease progression, and response/resistance to NSCLC cancer treatment. The use of the mTOR inhibitor everolimus in treatment of advanced NSCLC would be a novel therapeutic approach that proposes to logically manipulate the cell's regulatory pathways to enable control of tumor growth.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 85
- Patients with advanced (unresectable or metastatic) NSCLC
- Tissue sample of the metastatic or primary tumor available for pathology evaluation and molecular marker analyses
- Patients who have received ≤ 2 chemotherapy regimens, one of which must have included cisplatinum or carboplatin, and who have documented evidence of tumor progression (Arm 1)
- Patients who have received ≤ 2 chemotherapy regimens, one of which must have included cisplatinum or carboplatin as well as a small molecule EGFR inhibitor (as a separate regimen) with documented tumor progression despite at least 4 weeks therapy with either gefitinib or erlotinib (Arm 2)
- Concurrent therapy with agents used otherwise as anticancer therapy (for example, methotrexate for rheumatoid arthritis)
- Any investigational drug, other than EGFR inhibitor (Arm 2), within the preceding 4 weeks
- Chronic treatment with steroids or another immunosuppressive agent
- Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description previously treated with chemotherapy only RAD001 patients previously treated with chemotherapy only (at most 2 prior regimens one of which must have been platinum-based) and no EGFRI previously treated with chemotherapy + small RAD001 patients previously treated with chemotherapy (at most 2 prior regimens one of which must have been platinum-based) and with one small molecule EGFRI
- Primary Outcome Measures
Name Time Method Clinical efficacy based on the evaluation of objective tumor response rate (RR) until progressive disease or unacceptable toxicity.
- Secondary Outcome Measures
Name Time Method To investigate potential molecular markers predictive of clinical effect as long as patients are in the study To assess additional clinical efficacy of RAD001 as long as patients are in the study To assess the steady state levels of RAD001 in blood as long as patients are in the study To assess safety of RAD001 monotherapy as long as patients are in the study
Trial Locations
- Locations (2)
Nevada Cancer Institute
🇺🇸Las Vegas, Nevada, United States
MD Anderson Cancer Center, Department of Thoracic /Head and Neck Medical Oncology
🇺🇸Houston, Texas, United States